Conafay Group on Behalf of Antibiotics Working Group

Representing the voice of emerging antibiotics industry

Based in NC

🤖

AI Overview

With $1.6M in lobbying spend across 26 quarterly filings, Conafay Group on Behalf of Antibiotics Working Group is a significant lobbying presence.

$1.6M
Total Lobbying Spend
26
Quarterly Filings
1
Lobbying Firms Used
6
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$240K
2019$270K
2020$210K
2021$280K
2022$280K
2023$170K
2024$10K
2025$140K

Lobbying Firms

THE CONAFAY GROUP, LLC

What They Lobby For

  • Legislation related to DISARM and R&D tax credit.
  • Legislation related to DISARM and R&D tax credit and biologics.
  • Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cures 2.0 and COVID19 response packages.
  • Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
  • Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
  • Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY25 Appropriations and PAHPA.
  • Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY25 Appropriations and PAHPA.
  • Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.